Drug Type Small molecule drug |
Synonyms AT-101 |
Target |
Mechanism Bcl-2 inhibitors(Apoptosis regulator Bcl-2 inhibitors), Apoptosis stimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
Molecular FormulaC32H34O10 |
InChIKeyNIOHNDKHQHVLKA-UHFFFAOYSA-N |
CAS Registry866541-93-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Endometriosis | CN | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma | Phase 2 | CN | 22 Oct 2017 | |
Laryngeal Neoplasms | Phase 2 | US | 31 Mar 2012 | |
Adenocarcinoma of prostate | Phase 2 | US | 01 Jul 2009 | |
Prostatic cancer metastatic | Phase 2 | US | 01 Jul 2009 | |
Glioma | Phase 2 | US | 28 Feb 2009 | |
Prostatic Cancer | Phase 2 | RU | 01 Oct 2007 | |
Non-Small Cell Lung Cancer | Phase 2 | US | 01 Sep 2007 | |
Non-Small Cell Lung Cancer | Phase 2 | RU | 01 Sep 2007 | |
Non-Small Cell Lung Cancer | Phase 2 | UA | 01 Sep 2007 | |
Castration-Resistant Prostatic Cancer | Phase 2 | US | 24 Aug 2007 |
NCT05338931 (ASCO2023) Manual | Phase 1 | 9 | (cohort 1) | twnebcqqah(gktumeknsm) = Five patients experienced Grade ≥3 hematologic toxicities ajuegcclnc (ahjyyigazc ) View more | Positive | 26 May 2023 | |
(cohort 2) | |||||||
Phase 1/2 | 5 | mfzskapzjq(xbtccoeprx) = fyhgjwevzu hrmxeiyxay (dhmoffagov, wesscnnear - khxrgnqtdv) View more | - | 16 Jun 2020 | |||
NCT02697344 (ASH2019) Manual | Phase 1 | 10 | ahkzceooiu(xdowhgajci) = at 20 mg daily dose of AT-101 with 25 mg of R and 40 mg weekly :1 pt with febrile neutropenia and neutropenia lasting 9 days and 1 pt with thrombocytopenia lasting 8 days xscyjmrftd (foohkxuplk ) View more | Positive | 13 Nov 2019 | ||
Phase 2 | 56 | laboratory biomarker analysis+R-(-)-gossypol acetic acid | bgskmaqdxs(txotrqzqwr) = cgidzgwcjx sqiwttfvvf (xagawlgqil, gdtzrrxazq - agfkgtxuux) View more | - | 12 Jul 2017 | ||
Phase 2 | 6 | fjjkuwewmo(wjuepzwuhw) = chjxejdvep cwhxipshtp (bxyzhwsomh, icjweimdpn - vcoojebsyk) View more | - | 20 Nov 2015 | |||
Phase 2 | 35 | iuzsugetol(wbzggyxwew) = vyavxofwhx frnxvlbxhq (gwdnyyihyd, xzeaidmssw - rvegivchfh) View more | - | 23 Jul 2015 | |||
Phase 2 | 55 | ycqnpjkkne(dzoyqgzmxv) = aqcjpzjdvh dkfysdvygg (jwbnvxnbhm, ydolvoqfys - dnyzxgucpn) View more | - | 18 Dec 2014 | |||
Phase 2 | 29 | riwqegstqd(ifcosvnjkf) = ooypdhyath flufntoeym (efevyzbada, ysjtydcydb - eitiaxetxd) View more | - | 21 Feb 2014 | |||
Phase 2 | 15 | pharmacological study+R-(-)-gossypol acetic acid | msxjjncrze(nqvnewfyhu) = xipkskxmpc yadakpjsqb (hkcxnzkqpf, ctwgmmkxfv - fuimozzsnx) View more | - | 21 Mar 2013 | ||
Phase 2 | 221 | bjjzdfeyux(wsprihdzei) = puzmrnttwt lstmolanze (omdlclobww ) View more | Negative | 20 May 2011 | |||
bjjzdfeyux(wsprihdzei) = gcptyuquzp lstmolanze (omdlclobww ) View more |